Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Lodewyk F A Wessels x
  • Refine by access: All content x
Clear All Modify Search
Suzan Stelloo Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Suzan Stelloo in
Google Scholar
PubMed
Close
,
Simon Linder Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Simon Linder in
Google Scholar
PubMed
Close
,
Ekaterina Nevedomskaya Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Ekaterina Nevedomskaya in
Google Scholar
PubMed
Close
,
Eider Valle-Encinas Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Eider Valle-Encinas in
Google Scholar
PubMed
Close
,
Iris de Rink Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Iris de Rink in
Google Scholar
PubMed
Close
,
Lodewyk F A Wessels Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Faculty of EEMCS, Delft University of Technology, Delft, The Netherlands

Search for other papers by Lodewyk F A Wessels in
Google Scholar
PubMed
Close
,
Henk van der Poel Division of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Search for other papers by Henk van der Poel in
Google Scholar
PubMed
Close
,
Andries M Bergman Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Andries M Bergman in
Google Scholar
PubMed
Close
, and
Wilbert Zwart Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands

Search for other papers by Wilbert Zwart in
Google Scholar
PubMed
Close

Prostate cancer development and progression is largely dependent on androgen receptor (AR) signaling. AR is a hormone-dependent transcription factor, which binds to thousands of sites throughout the human genome to regulate expression of directly responsive genes, including pro-survival genes that enable tumor cells to cope with increased cellular stress. ERN1 and XBP1 – two key players of the unfolded protein response (UPR) – are among such stress-associated genes. Here, we show that XBP1 levels in primary prostate cancer are associated with biochemical recurrence in five independent cohorts. Patients who received AR-targeted therapies had significantly lower XBP1 expression, whereas expression of the active form of XBP1 (XBP1s) was elevated. In vitro results show that AR-induced ERN1 expression led to increased XBP1s mRNA and protein levels. Furthermore, ChIP-seq analysis revealed that XBP1s binds enhancers upon stress stimuli regulating genes involved in UPR processes, eIF2 signaling and protein ubiquitination. We further demonstrate genomic overlap of AR- and XBP1s-binding sites, suggesting genomic conversion of the two signaling cascades. Transcriptomic effects of XBP1 were further studied by knockdown experiments, which lead to decreased expression of androgen-responsive genes and UPR genes. These results suggest a two-step mechanism of gene regulation, which involves androgen-induced expression of ERN1, thereby enhancing XBP1 splicing and transcriptional activity. This signaling cascade may prepare the cells for the increased protein folding, mRNA decay and translation that accompanies AR-regulated tumor cell proliferation.

Restricted access